Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Opioid Receptors: Overview

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development and validation of a method for quantitation of CTx-1 for the assessment of biosimilarity of FKS518, a denosumab biosimilar.

Bioanalysis·2025

Same author

Mechanistic insights into sulfur source-driven physiological responses and metabolic reorganization in the fuel-biodesulfurizing <i>Rhodococcus qingshengii</i> IGTS8.

Applied and environmental microbiology·2023

Same author

Autosomal Dominant MPAN: Mosaicism Expands the Clinical Spectrum to Atypical Late-Onset Phenotypes.

Movement disorders : official journal of the Movement Disorder Society·2023

Same author

Phenotype and imaging features associated with APP duplications.

Alzheimer's research & therapy·2023

Same author

Biodesulfurization Induces Reprogramming of Sulfur Metabolism in Rhodococcus qingshengii IGTS8: Proteomics and Untargeted Metabolomics.

Microbiology spectrum·2021

Same author

Impaired brain insulin signalling in Parkinson's disease.

Neuropathology and applied neurobiology·2021

Search research articles

Related Experiment Video

Updated: May 31, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Endogenous morphine-like compound immunoreactivity increases in parkinsonism.

Giselle Charron¹, Evelyne Doudnikoff, Alexis Laux

¹University of Bordeaux, Institut des Maladies Neurodegeneratives, Bordeaux, France.

Brain : a Journal of Neurology

|July 12, 2011

Summary

Parkinson's disease surprisingly shows increased endogenous morphine levels in the brain. This upregulation, linked to dopamine loss, may contribute to Parkinson's symptoms like pain and depression.

Related Experiment Videos

Last Updated: May 31, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Area of Science:

Neuroscience
Neurochemistry

Background:

Endogenous morphine is synthesized in the central nervous system, with dopamine potentially crucial for its formation.
Parkinson's disease involves dopamine loss and is associated with central pain, prompting investigation into endogenous morphine regulation.

Purpose of the Study:

To investigate the regulation of endogenous morphine in the context of Parkinson's disease.
To characterize the cellular distribution and changes in endogenous morphine-like compounds in the parkinsonian brain.

Main Methods:

Characterized the distribution of endogenous morphine-like immunoreactive cells in the rat striatum.
Analyzed changes in medium spiny neurons' endogenous morphine-like immunoreactivity in normal, Parkinson's disease-like, and l-DOPA-treated models, including human Parkinson's disease patients.

Main Results:

Revealed a significant, unexpected upregulation of neuronal endogenous morphine-like immunoreactivity and levels in experimental and human Parkinson's disease.
Observed only partial normalization of these levels with l-DOPA treatment.

Conclusions:

Endogenous morphine formation is more complex than previously understood.
The parkinsonian brain exhibits a dramatic increase in endogenous morphine immunoreactivity.
Hypothesize this upregulation may be involved in Parkinson's symptoms such as fatigue, depression, and pain.